READ THE FULL STUDY »

A patented strain of Bacillus coagulans increased immune response to viral challenge

Postgraduate Medicine, 2009; 121(2): 114–118

Mira Baron

Abstract

Background:
Viral respiratory tract infection is the most common illness among humans. Probiotics have been known to enhance the immune system and, therefore, may represent a significant therapeutic advancement for treating viral respiratory tract infections.

Objective:
A controlled study was conducted to evaluate the effects of the patented GanedenBC30 probiotic (Bacillus coagulans GBI-30, 6086, marketed as Sustenex® [Ganeden Biotech, Inc., Mayfield Heights, OH] on the immune system when exposed to adenovirus and influenza in otherwise healthy adults.

Methods:
Ten healthy men and women (average age, 44 years) were instructed to consume 1 capsule of GanedenBC30 with water once a day for 30 days. At baseline and after completion of the 30-day treatment, blood levels of cytokines were measured in vitro after T-cell exposure to adenovirus and influenza A. Each participant served as his/her own control with baseline blood draw.

Results:
The use of GanedenBC30 significantly increased T-cell production of TNF-α in response to adenovirus exposure (P = 0.027) and influenza A (H3N2 Texas strain) exposure (P = 0.004), but it did not have a significant effect on the response to other strains of influenza. No serious adverse events were reported throughout the study.

Conclusions:
The patented GanedenBC30 probiotic may be a safe and effective therapeutic option for enhancing T-cell response to certain viral respiratory tract infections. 

READ THE FULL STUDY »

Ganeden is a science focused organization dedicated to bringing superior probiotics to markets that have been otherwise unmet by traditional solutions.

All Ganeden ingredients are made in the United States of America.